BiotechTube

Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + Carboplatin

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urothelial Carcinoma

Conditions

Urothelial Carcinoma

Trial Timeline

May 29, 2019 → Oct 21, 2027

NCT ID
NCT03967977

About Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + Carboplatin

Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + Carboplatin is a phase 3 stage product being developed by BeOne Medicines for Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03967977. Target conditions include Urothelial Carcinoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03967977Phase 3Recruiting

Competing Products

20 competing products in Urothelial Carcinoma

See all competitors
ProductCompanyStageHype Score
Dato-DXd + Carboplatin + Cisplatin + GemcitabineDaiichi SankyoPhase 2/3
65
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
Enfortumab vedotin + Pembrolizumab + Cisplatin + Carboplatin + GemcitabineAstellas PharmaPhase 3
77
PF-08634404 + Enfortumab VedotinAstellas PharmaPhase 1/2
41
Enfortumab vedotinAstellas PharmaPhase 1
33
AGS15EAstellas PharmaPhase 1
33
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
enfortumab vedotin (EV)Astellas PharmaPre-clinical
23
Enfortumab VedotinAstellas PharmaPhase 2
52
Enfortumab VedotinAstellas PharmaApproved
85
Enfortumab vedotinAstellas PharmaPhase 2
52
Enfortumab VedotinAstellas PharmaPre-clinical
23
enfortumab vedotinAstellas PharmaPhase 1
33
Eribulin Mesylate + AvelumabEisaiPhase 1
33
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
77
KHK2455 + AvelumabKyowa KirinPhase 1
33
Nivolumab 100 MG in 10 ML InjectionOno PharmaceuticalPhase 2
52
Nivolumab + Ipilimumab + Gemcitabine + Cisplatin + CarboplatinOno PharmaceuticalPhase 3
77
Ramucirumab + Docetaxel + PlaceboEli LillyPhase 3
77

Other Products from BeOne Medicines

ZanubrutinibApproved
82
Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007Phase 3
74
Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-FluorouracilPhase 3
74
Zanubrutinib + Bendamustine + Rituximab + VenetoclaxPhase 3
74
Sonrotoclax + Zanubrutinib + PlaceboPhase 3
74